Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
6(75.0%)
Phase 1
1(12.5%)
Phase 3
1(12.5%)
8Total
Phase 2(6)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT06856213Phase 2Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Role: lead

NCT04282109Phase 2Completed

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Role: lead

NCT05784012Phase 1Recruiting

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Role: lead

NCT04970134Active Not Recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma

Role: lead

NCT02268695Phase 2Completed

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

Role: collaborator

NCT04672772Completed

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Role: lead

NCT04632173Unknown

Head and Neck cancERs International cOviD-19 collabOraTion

Role: collaborator

NCT03887442Phase 2Terminated

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

Role: lead

NCT00716391Phase 3Completed

TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.

Role: lead

NCT01264328Phase 2Completed

Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer

Role: lead

NCT00765011Phase 2Completed

TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer

Role: lead

All 11 trials loaded